Economical Evaluation of Cancer Types Using Intensity-Modulated Radiation Therapy Compared to 3D Conformal Radiation Therapy: A Systematic Review
-
Vahid Alipour
,
Aziz Rezapour
,
Amin Adel
,
Arefeh Pourtaleb
,
Mitra Bazrafshan
,
Mozhgan Sadat Ghaem Mohammadi
,
Reza Jahangiri
Abstract
Background: Cancer is the second most common cause of death worldwide. Economic evaluation of cancer treatment to reduce costs can save the health care system millions of dollars while optimizing care. Therefore, this systematic review aimed to study the economic evaluation of cancer treatment using intermediate intensity radiation therapy (IMRT) compared to conventional 3D conformal radiation therapy (3D-CRT).
Methods: Literatures from PubMed, Embase, Cochran Library, Google scholar, Scopus and Iranian databases were retrieved since Jan 2000 to Apr 2020 for eligible English studies. The quality of the studies was evaluated using Cheers' checklist and then the textual data were analyzed manually by content analysis method.
Results: Overall, 1790 articles were retrieved, of which 12 studies were reviewed. The article quality score ranged from 14.5 to 23 out of a maximum of 24 points. Eleven studies referred to cost-effectiveness analysis and one study referred to cost-utility analysis. Studies have been conducted in the United States, Canada, Australia, Brazil, the Netherlands, the United Kingdom, and Hungary. IMRT appears to be a cost-effective treatment strategy for rectal cancer, soft tissue sarcoma, and localized carcinoma of the pharynx, and for prostate cancer in terms of prolonging survival, but it is a cost-effective treatment strategy for head cancer. In addition, the neck was not in India's cancer control program.
Conclusion: The results can help to decide whether to use radiation therapy and radiotherapy in the standard treatment path. Furthermore, they underline that IMRT treatment technique was cost effective for a long-time care service.
1. Salminen E, Izewska J, Andreo P (2005). IAEA's role in the global management of cancer-focus on upgrading radiother-apy services. Acta Oncologica, 44:816-824.
2. Featherstone H, Whitham L (2010). The cost of cancer. ed. Policy Exchange London.
3. Ferlay J (2010). GLOBOCAN 2008 v1. 2, Cancer incidence and mortality world-wide: IARC Cancer Base No. 10. http://globocan. iarc
4. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Mar-tínez G, Frenel J-S, Karamouzis M (2018). Global cancer control: respond-ing to the growing burden, rising costs and inequalities in access. ESMO Open, 3:e000285.
5. Guadagnolo BA, Liu CC, Cormier JN, Du XL (2010). Evaluation of trends in the use of intensity‐modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population‐based cohort. Cancer, 116:3505-3512.
6. Ezzell GA, Galvin JM, Low D, et al (2003). Guidance document on delivery, treat-ment planning, and clinical implemen-tation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys, 30:2089-2115.
7. James BY, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP (2014). Stereotac-tic body radiation therapy versus inten-sity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol, 32:1195.
8. Reyngold M, Niland J, Ter Veer A, et al (2018). Trends in intensity modulated radiation therapy use for locally ad-vanced rectal cancer at National Com-prehensive Cancer Network centers. Adv Radiat Oncol, 3:34-41.
9. Konski A, Watkinsbruner D, Feigenberg S, et al (2004). Intensity modulated radia-tion therapy (IMRT) is a cost-effective treatment for intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys, 60:S144-S144.
10. Mell LK, Mehrotra AK, Mundt AJ (2005). Intensity‐modulated radiation therapy use in the US, 2004. Cancer, 104:1296-1303.
11. Rezapour A, Faradonbeh SB, Alipour V, Yusefvand M (2018). Effectiveness of re-vascularization interventions compared with medical therapy in patients with is-chemic cardiomyopathy: A systematic review protocol. Medicine (Baltimore), 97(10):e9958.
12. Konski A, Watkins-Bruner D, Feigenberg S, et al (2006). Using decision analysis to determine the cost-effectiveness of in-tensity-modulated radiation therapy in the treatment of intermediate risk pros-tate cancer. Int J Radiat Oncol Biol Phys, 66:408-15.
13. Hodges JC, Beg MS, Das P, Meyer J (2014). Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation thera-py for anal cancer. Int J Radiat Oncol Biol Phys, 89:773-83.
14. Richard P, Phillips M, Smith W, Davidson D, Kim E, Kane G (2016). Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Preoperative Treatment of Extremity Soft Tissue Sarcomas. Int J Radiat Oncol Biol Phys, 95:999-1008.
15. Zemplenyi AT, Kalo Z, Kovacs G, et al (2018). Cost-effectiveness analysis of in-tensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Eur J Cancer Care (Engl), 27 (1).
16. Chauhan AS, Prinja S, Ghoshal S, Verma R (2020). Cost-effectiveness of treating head and neck cancer using intensity-modulated radiation therapy: implica-tions for cancer control program in In-dia. Int J Technol Assess Health Care, 36:492-499.
17. Carter HE, Martin A, Schofield D, et al (2014). A decision model to estimate the cost-effectiveness of intensity modulat-ed radiation therapy (IMRT) compared to three dimensional conformal radia-tion therapy (3DCRT) in patients receiv-ing radiotherapy to the prostate bed. Radiother Oncol, 112:187-93.
18. Hummel SR, Stevenson MD, Simpson EL, Staffurth J (2012). A model of the cost-effectiveness of intensity-modulated ra-diotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol), 24:e159-67.
19. Kohler RE, Sheets NC, Wheeler SB, Nut-ting C, Hall E, Chera BS (2013). Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radia-tion therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys, 87:683-9.
20. Marta GN, Weltman E, Ferrigno R (2018). Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis. Rev Assoc Med Bras (1992), 64:318-323.
21. Yong JH, Beca J, McGowan T, Bremner KE, Warde P, Hoch JS (2012). Cost-effectiveness of intensity-modulated ra-diotherapy in prostate cancer. Clin Oncol (R Coll Radiol), 24:521-31.
22. Konski A (2005). Cost-effectiveness of in-tensity-modulated radiation therapy. Expert Rev Pharmacoecon Outcomes Res, 5:137-40.
23. Yong JH, Beca J, O'Sullivan B, et al (2012). Cost-effectiveness of intensity-modulated radiotherapy in oropharyn-geal cancer. Clin Oncol (R Coll Radiol), 24:532-8.
24. Al-Badriyeh D, Alameri M, Al-Okka R (2017). Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influ-ence of funding. BMJ Open, 7:e012648.
25. Huber B, Doyle J (2010). Oncology drug development and value-based medicine. Quintiles, Copy-right.https://www.slideshare.net/Quintiles/oncology-drugdevelopmentandvaluebasedmedi-cine
26. Rezapour A, Hosseinijebeli SS, Faradonbeh SB (2021). Economic evaluation of E-health interventions compared with al-ternative treatments in older persons’ care: A systematic review. J Educ Health Promot, 10:134.
27. Kanavos P (2006). The rising burden of cancer in the developing world. Ann On-col, 17:viii15-viii23.
28. Sanghera S, Coast J, Martin RM, Donovan JL, Mohiuddin S (2018). Cost-effectiveness of prostate cancer screen-ing: a systematic review of decision-analytical models. BMC Cancer, 18:1-15.
29. Konski A (2018). Cost effectiveness of prostate cancer radiotherapy. Transl An-drol Urol, 7:371-7.
2. Featherstone H, Whitham L (2010). The cost of cancer. ed. Policy Exchange London.
3. Ferlay J (2010). GLOBOCAN 2008 v1. 2, Cancer incidence and mortality world-wide: IARC Cancer Base No. 10. http://globocan. iarc
4. Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Mar-tínez G, Frenel J-S, Karamouzis M (2018). Global cancer control: respond-ing to the growing burden, rising costs and inequalities in access. ESMO Open, 3:e000285.
5. Guadagnolo BA, Liu CC, Cormier JN, Du XL (2010). Evaluation of trends in the use of intensity‐modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population‐based cohort. Cancer, 116:3505-3512.
6. Ezzell GA, Galvin JM, Low D, et al (2003). Guidance document on delivery, treat-ment planning, and clinical implemen-tation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys, 30:2089-2115.
7. James BY, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP (2014). Stereotac-tic body radiation therapy versus inten-sity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol, 32:1195.
8. Reyngold M, Niland J, Ter Veer A, et al (2018). Trends in intensity modulated radiation therapy use for locally ad-vanced rectal cancer at National Com-prehensive Cancer Network centers. Adv Radiat Oncol, 3:34-41.
9. Konski A, Watkinsbruner D, Feigenberg S, et al (2004). Intensity modulated radia-tion therapy (IMRT) is a cost-effective treatment for intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys, 60:S144-S144.
10. Mell LK, Mehrotra AK, Mundt AJ (2005). Intensity‐modulated radiation therapy use in the US, 2004. Cancer, 104:1296-1303.
11. Rezapour A, Faradonbeh SB, Alipour V, Yusefvand M (2018). Effectiveness of re-vascularization interventions compared with medical therapy in patients with is-chemic cardiomyopathy: A systematic review protocol. Medicine (Baltimore), 97(10):e9958.
12. Konski A, Watkins-Bruner D, Feigenberg S, et al (2006). Using decision analysis to determine the cost-effectiveness of in-tensity-modulated radiation therapy in the treatment of intermediate risk pros-tate cancer. Int J Radiat Oncol Biol Phys, 66:408-15.
13. Hodges JC, Beg MS, Das P, Meyer J (2014). Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation thera-py for anal cancer. Int J Radiat Oncol Biol Phys, 89:773-83.
14. Richard P, Phillips M, Smith W, Davidson D, Kim E, Kane G (2016). Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Preoperative Treatment of Extremity Soft Tissue Sarcomas. Int J Radiat Oncol Biol Phys, 95:999-1008.
15. Zemplenyi AT, Kalo Z, Kovacs G, et al (2018). Cost-effectiveness analysis of in-tensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Eur J Cancer Care (Engl), 27 (1).
16. Chauhan AS, Prinja S, Ghoshal S, Verma R (2020). Cost-effectiveness of treating head and neck cancer using intensity-modulated radiation therapy: implica-tions for cancer control program in In-dia. Int J Technol Assess Health Care, 36:492-499.
17. Carter HE, Martin A, Schofield D, et al (2014). A decision model to estimate the cost-effectiveness of intensity modulat-ed radiation therapy (IMRT) compared to three dimensional conformal radia-tion therapy (3DCRT) in patients receiv-ing radiotherapy to the prostate bed. Radiother Oncol, 112:187-93.
18. Hummel SR, Stevenson MD, Simpson EL, Staffurth J (2012). A model of the cost-effectiveness of intensity-modulated ra-diotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol), 24:e159-67.
19. Kohler RE, Sheets NC, Wheeler SB, Nut-ting C, Hall E, Chera BS (2013). Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radia-tion therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys, 87:683-9.
20. Marta GN, Weltman E, Ferrigno R (2018). Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis. Rev Assoc Med Bras (1992), 64:318-323.
21. Yong JH, Beca J, McGowan T, Bremner KE, Warde P, Hoch JS (2012). Cost-effectiveness of intensity-modulated ra-diotherapy in prostate cancer. Clin Oncol (R Coll Radiol), 24:521-31.
22. Konski A (2005). Cost-effectiveness of in-tensity-modulated radiation therapy. Expert Rev Pharmacoecon Outcomes Res, 5:137-40.
23. Yong JH, Beca J, O'Sullivan B, et al (2012). Cost-effectiveness of intensity-modulated radiotherapy in oropharyn-geal cancer. Clin Oncol (R Coll Radiol), 24:532-8.
24. Al-Badriyeh D, Alameri M, Al-Okka R (2017). Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influ-ence of funding. BMJ Open, 7:e012648.
25. Huber B, Doyle J (2010). Oncology drug development and value-based medicine. Quintiles, Copy-right.https://www.slideshare.net/Quintiles/oncology-drugdevelopmentandvaluebasedmedi-cine
26. Rezapour A, Hosseinijebeli SS, Faradonbeh SB (2021). Economic evaluation of E-health interventions compared with al-ternative treatments in older persons’ care: A systematic review. J Educ Health Promot, 10:134.
27. Kanavos P (2006). The rising burden of cancer in the developing world. Ann On-col, 17:viii15-viii23.
28. Sanghera S, Coast J, Martin RM, Donovan JL, Mohiuddin S (2018). Cost-effectiveness of prostate cancer screen-ing: a systematic review of decision-analytical models. BMC Cancer, 18:1-15.
29. Konski A (2018). Cost effectiveness of prostate cancer radiotherapy. Transl An-drol Urol, 7:371-7.
| Files | ||
| Issue | Vol 52 No 7 (2023) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i7.13237 | |
| Keywords | ||
| Cancer Radiation therapy Radiotherapy Economic evaluation | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Alipour V, Rezapour A, Adel A, Pourtaleb A, Bazrafshan M, Ghaem Mohammadi M, Jahangiri R. Economical Evaluation of Cancer Types Using Intensity-Modulated Radiation Therapy Compared to 3D Conformal Radiation Therapy: A Systematic Review. Iran J Public Health. 2023;52(7):1355-1366.
